Connect your AI

Amylyx Pharmaceuticals, Inc. AMLX Price / book

Price / book at other companies

MBX Biosciences, Inc.MBX

3.2×+2.2×

Viking TherapeuticsVKTX

7.5×+4.3×

Beam TherapeuticsBEAM

2.1×+0.4×

Crinetics PharmaceuticalsCRNX

3×+0.5×

Agios PharmaceuticalsAGIO

1.8×+0.6×

Rhythm Pharmaceuticals, Inc.RYTM

48.3×-128×

Other financials

Income statement

Revenue-—

Gross profit-—

Operating income-$43.8M-15.8%

Net income-$41.3M-15.0%

EPS (diluted)-$0.37+11.9%

Balance sheet

Cash & equivalents$229.1M+283%

Total debt$5.6M+307%

Total equity$273.2M+35.6%

Total assets$293.6M+33.7%

Cash flow

Operating cash flow-$36.9M+7.4%

CapEx$86.0K+330%

Free cash flow-$28.0M+52.6%

Valuation

Market cap$1.82B+390%

Enterprise value$1.6B+414%

Profitability

Gross margin100%+6.9pp

Operating margin-47,349.8%-47,409pp

Net margin-45,096.2%-45,152pp

FCF margin-39,826.7%-39,847pp

Returns & leverage

Return on equity-63.3%-12.2pp

Debt / equity0×0.0×

Current ratio17.9×+5.8×

Where this comes from

Calculated from Amylyx Pharmaceuticals, Inc.’s reported figures.

market cap/total stockholders equity=5.6×

Based on the most recent quarter.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amylyx Pharmaceuticals, Inc.'s price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s price / book?: Amylyx Pharmaceuticals, Inc. (AMLX) reported price / book of 5.6× in Q1 2026.
How has Amylyx Pharmaceuticals, Inc.'s price / book changed year-over-year?: Amylyx Pharmaceuticals, Inc.'s price / book increased by 261.2% year-over-year, from 1.6× to 5.6×.
What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s price / book?: Over 3 years (2022 to 2025), Amylyx Pharmaceuticals, Inc.'s price / book has grown at a -15.1% compound annual growth rate (CAGR), from 7.1× to 4.3×.
What does price / book mean?: Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.